Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00649818 | Fasting Study of Lorazepam Tablets 2 mg and Ativan Tablets 2 mg | PHASE1 | COMPLETED | 28 | — | — | Dec 1, 2004 | Dec 1, 2004 | Apr 24, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Lorazepam Tablets 2 mg |
| 2 | ACTIVE_COMPARATOR | Ativan Tablets 2 mg |
| Name | Type | Description |
|---|---|---|
| Lorazepam Tablets 2 mg | DRUG | 2mg, single dose fasting |
| Ativan Tablets 2 mg | DRUG | 2mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum (Beta HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administratio...